Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA340130 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Gene expression analysis of renal cell carcinoma cell line A-498 after 3-hour treatment with englerin A.
| PRJNA340129 | ENA
Project description:Gene expression analysis of renal cell carcinoma cell line A-498 after 8-hour treatment with englerin A.
| PRJNA340131 | ENA
Project description:Treatment of renal cell carcinoma cell line A-498 with zebularine
| PRJNA224109 | ENA
Project description:Treatment of renal cell carcinoma cell line A-498 with zebularine
2025-01-24 | E-GEOD-51627 | ExpressionAtlas
Project description:786-0 renal cell carcinoma cell line Everolimus treatment
| PRJNA389812 | ENA
Project description:Mathematical modeling of regulatory T cell effects on renal cell carcinoma treatment
Lisette dePillis 1, , Trevor Caldwell 2, , Elizabeth Sarapata 2, and Heather Williams 2,
1.
Department of Mathematics, Harvey Mudd College, Claremont, CA 91711
2.
Harvey Mudd College, Claremont, CA 91711, United States, United States, United States
Abstract
We present a mathematical model to study the effects of the regulatory T cells (Treg) on Renal Cell Carcinoma (RCC) treatment with sunitinib. The drug sunitinib inhibits the natural self-regulation of the immune system, allowing the effector components of the immune system to function for longer periods of time. This mathematical model builds upon our non-linear ODE model by de Pillis et al. (2009) [13] to incorporate sunitinib treatment, regulatory T cell dynamics, and RCC-specific parameters. The model also elucidates the roles of certain RCC-specific parameters in determining key differences between in silico patients whose immune profiles allowed them to respond well to sunitinib treatment, and those whose profiles did not.
Simulations from our model are able to produce results that reflect clinical outcomes to sunitinib treatment such as: (1) sunitinib treatments following standard protocols led to improved tumor control (over no treatment) in about 40% of patients; (2) sunitinib treatments at double the standard dose led to a greater response rate in about 15% the patient population; (3) simulations of patient response indicated improved responses to sunitinib treatment when the patient's immune strength scaling and the immune system strength coefficients parameters were low, allowing for a slightly stronger natural immune response.
Keywords: Renal cell carcinoma, mathematical modeling., sunitinib, immune system, regulatory T cells.
2024-09-02 | BIOMD0000000908 | BioModels
Project description:This analysis was performed among 786-o renal cell carcinoma cell line, its sunitinib resistant cell, and sunitinib resistant Hif2a knock out cell.
2017-08-09 | PXD007222 | JPOST Repository
Project description:Gene set enrichment analysis and ingenuity pathway analysis of metastatic clear cell renal cell carcinoma cell line
| PRJNA312839 | ENA
Project description:Gene expression analysis in renal cell carcinoma
| PRJNA105869 | ENA